Molecular basis of co-targeting prostate tumor and stroma
β Scribed by Fan Yeung; Leland W. K. Chung
- Publisher
- John Wiley and Sons
- Year
- 2002
- Tongue
- English
- Weight
- 97 KB
- Volume
- 85
- Category
- Article
- ISSN
- 0730-2312
No coin nor oath required. For personal study only.
β¦ Synopsis
Prostate cancer is one of the leading causes of cancer death in Northern American men. The lethal phenotypes of human prostate cancer are characterized by progression to androgen-independence (Al) and a propensity to form osseous metastases. In approximately 80% of cases, prostate cancer colonizes bone and elicits a characteristic osteoblastic reaction. The bone metastases are initially sensitive to androgen deprivation treatments, but with time the cancer will eventually progress into an Al stage for which there is currently no effective treatment. Once initial hormonal therapy has failed, median survival of prostate cancer patients with bone metastases is less than 1 year (Tu et al. [2001] Lancet 357:336-341). Novel therapeutic and preventive strategies are needed to decrease morbidity and mortality of this disease.
π SIMILAR VOLUMES
Genetically engineered mouse models have been generated to study the molecular basis of prostate cancer (PCa) development, progression, and metastasis. Selection of a prostate-specific promoter, such as the probasin (PB) and prostate specific antigen (PSA) promoters, is critical for generating suffi
## Abstract The lowβaffinity nerve growth factor receptor p75^NTR^ is a 75βkDa glycoprotein that belongs to the tumor necrosis factor receptor superfamily and has been implicated in the induction of apoptosis in various tissues and cell lines. Immunohistochemistry on tissue sections from radical pr